Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates [Yahoo! Finance]
Immunome, Inc. (IMNM)
Company Research
Source: Yahoo! Finance
Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened management team to support execution of highly focused strategy $371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027 SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced financial results for the year ended December 31, 2024, and highlighted recent corporate accomplishments. "Zentalis reported significant progress in the devel
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome, Inc. (NASDAQ: IMNM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $33.00 price target on the stock.MarketBeat
- Immunome, Inc. (NASDAQ: IMNM) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $30.00 price target on the stock.MarketBeat
- Immunome, Inc. (NASDAQ: IMNM) had its price target lowered by analysts at Guggenheim from $35.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- Immunome Reports Full Year 2024 Financial Results and Provides Business UpdateBusiness Wire
- Immunome, Inc. (NASDAQ: IMNM) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $20.00 price target on the stock.MarketBeat
IMNM
Earnings
- 11/13/24 - Miss
IMNM
Sec Filings
- 3/28/25 - Form 4
- 3/26/25 - Form 4
- 3/26/25 - Form 4
- IMNM's page on the SEC website